본문 바로가기
KERD
논문KCI 등재

Probiotics and the Role of Dietary Substrates in Maintaining the Gut Health: Use of Live Microbes and Their Products for Anticancer Effects against Colorectal Cancer

Xu Yi|Wu Xiahui|Li Yan|Liu Xuejie|Fang Lijian|Jiang Ziyu
한국미생물·생명공학회 (The Korean Society For Microbiology And Biotechnology)|2024.10|Journal of Microbiology and Biotechnology|제34권 제10호|pp. 1933-1946|DOI 10.4014/jmb.2403.03056

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

probioticsGut microbiomeantitumoreubiosis diet
주제분류생물학

초록

The gut microbiome is an important and the largest endocrine organ linked to the microbes of the GI tract. The bacterial, viral and fungal communities are key regulators of the health and disease status in a host at hormonal, neurological, immunological, and metabolic levels. The useful microbes can compete with microbes exhibiting pathogenic behavior by maintaining resistance against their colonization, thereby maintaining eubiosis. As diagnostic tools, metagenomic, proteomic and genomic approaches can determine various microbial markers in clinic for early diagnosis of colorectal cancer (CRC). Probiotics are live non-pathogenic microorganisms such as lactic acid bacteria, Bifidobacteria, Firmicutes and Saccharomyces that can help maintain eubiosis when administered in appropriate amounts. In addition, the type of dietary intake contributes substantially to the composition of gut microbiome. The use of probiotics has been found to exert antitumor effects at preclinical levels and promote the antitumor effects of immunotherapeutic drugs at clinical levels. Also, modifying the composition of gut microbiota by Fecal Microbiota Transplantation (FMT), and using live lactic acid producing bacteria such as Lactobacillus, Bifidobacteria and their metabolites (termed postbiotics) can contribute to immunomodulation of the tumor microenvironment. This can lead to tumor-preventive effects at early stages and antitumor effects after diagnosis of CRC. To conclude, probiotics are presumably found to be safe to use in humans and are to be studied further to promote their appliance at clinical levels for management of CRC.

Abstract

The gut microbiome is an important and the largest endocrine organ linked to the microbes of the GI tract. The bacterial, viral and fungal communities are key regulators of the health and disease status in a host at hormonal, neurological, immunological, and metabolic levels. The useful microbes can compete with microbes exhibiting pathogenic behavior by maintaining resistance against their colonization, thereby maintaining eubiosis. As diagnostic tools, metagenomic, proteomic and genomic approaches can determine various microbial markers in clinic for early diagnosis of colorectal cancer (CRC). Probiotics are live non-pathogenic microorganisms such as lactic acid bacteria, Bifidobacteria, Firmicutes and Saccharomyces that can help maintain eubiosis when administered in appropriate amounts. In addition, the type of dietary intake contributes substantially to the composition of gut microbiome. The use of probiotics has been found to exert antitumor effects at preclinical levels and promote the antitumor effects of immunotherapeutic drugs at clinical levels. Also, modifying the composition of gut microbiota by Fecal Microbiota Transplantation (FMT), and using live lactic acid producing bacteria such as Lactobacillus, Bifidobacteria and their metabolites (termed postbiotics) can contribute to immunomodulation of the tumor microenvironment. This can lead to tumor-preventive effects at early stages and antitumor effects after diagnosis of CRC. To conclude, probiotics are presumably found to be safe to use in humans and are to be studied further to promote their appliance at clinical levels for management of CRC.

참고문헌 (118)

  1. Thursby E, "Introduction to the human gut microbiota", Biochem. J, 474, pp.1823~1836 (2017)
  2. Afzaal M, "Human gut microbiota in health and disease : unveiling the relationship", Front. Microbiol, 13, pp.999001~ (2022)
  3. Guinane CM, "Role of the gut microbiota in health and chronic gastrointestinal disease : understanding a hidden metabolic organ", Therap. Adv. Gastroenterol, 6, pp.295~308 (2013)
  4. Lee LH, "Human microbiome : symbiosis to pathogenesis", Front. Microbiol, 12, pp.605783~ (2021)
  5. Pandey H, "Gut microbiota in colorectal cancer : biological role and therapeutic opportunities", Cancers, 15, pp.866~ (2023)
  6. Wong CC, "Gut microbiota in colorectal cancer development and therapy", Nat. Rev. Clin. Oncol, 20, pp.429~452 (2023)
  7. Kim J, "Potential role of the gut microbiome in colorectal cancer progression", Front. Immunol, 12, pp.807648~ (2022)
  8. Li M, "Symbiotic gut microbes modulate human metabolic phenotypes", Proc. Natl. Acad. Sci. USA, 105, pp.2117~2122 (2008)
  9. Merenstein D, "Emerging issues in probiotic safety : 2023perspectives", Gut Microbes, 15, pp.2185034~ (2023)
  10. Latif A, "Probiotics : mechanism of action, health benefits and their application in food industries", Front. Microbiol, 14, pp.1216674~ (2023)
  11. Das TK, "Current status of probiotic and related health benefits", Appl. Food Res, 2, pp.100185~ (2022)
  12. Stojanov S, "The influence of probiotics on the firmicutes", bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease, 2020, pp.8, 1715~
  13. Kareena A, "In vitro evaluation of probiotic bacteria and yeast growth, pH changes and metabolites produced in a pure culture system using protein base products with various added carbon sources", Food Sci. Technol, 42, pp.e18321~ (2021)
  14. Soemarie YB, "Fermented foods as probiotics : a review", J. Adv. Pharm. Technol. Res, 12, pp.335~339 (2021)
  15. Olson DW, "Probiotic Incorporation into yogurt and various novel yogurt-based products", Appl. Sci, 12, pp.12607~ (2022)
  16. Sanders M, "Probiotics for human use", Nutr. Bull, 43, pp.212~225 (2018)
  17. Fijan S, "Microorganisms with claimed probiotic properties : an overview of recent literature", Int. J. Environ. Res. Public Health, 11, pp.4745~4767 (2014)
  18. Stiles ME, "Lactic acid bacteria of foods and their current taxonomy", Int. J. Food Microbiol, 36, pp.1~29 (1997)
  19. Abid R, "Probiotic yeast Saccharomyces : back to nature to improve human health", J. Fungi, 8, pp.444~ (2022)
  20. Alhhazmi AA, "Gut Microbial and associated metabolite markers for colorectal cacncer diagnosis", Microorganisms, 11, pp.2037~ (2023)
  21. Zwezerijnen-Jiwa FH, "A systematic review of microbiome-derived biomarkers for early colorectal cancer detection", Neoplasia, 36, pp.100868~ (2023)
  22. Yu L, "A systematic review of microbial markers for risk prediction of colorectal neoplasia", Br. J. Cancer, 126, pp.1318~1328 (2022)
  23. Wu Y, "Identification of microbial markers across populations in early detection of colorectal cancer", Nat. Commun, 12, pp.3063~ (2021)
  24. Jiang Z, "Human gut-microbiome interplay : analysis of clinical studies for the emerging roles of diagnostic microbiology in inflammation, oncogenesis and cancer management", Infect. Genet. Evol, 93, pp.104946~ (2021)
  25. Sun Y, "Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis", Nat. Commun, 13, pp.2757~ (2022)
  26. Zhang Z, "Identification of faecal extracellular vesicles as novel biomarkers for the non-invasive diagnosis and prognosis of colorectal cancer", J. Extracell. Vesicles, 12, pp.12300~ (2023)
  27. Ghazanfar S, "Identification of actin beta-like 2(ACTBL2)as novel, upregulated protein in colorectal cancer", J. Proteomics, 152, pp.33~40 (2017)
  28. Hao JJ, "Comprehensive proteomic characterization of the human colorectal carcinoma reveals signature proteins and perturbed pathways", Sci. Rep, 7, pp.42436~ (2017)
  29. Harlid S, "A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk", Sci. Rep, 11, pp.5151~ (2021)
  30. Rho J-h, "Protein and glycomic plasma markers for early detection of adenoma and colon cancer", Gut, 67, pp.473~484 (2018)
  31. Redondo M, "Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas", Histopathology, 256, pp.932~936 (2010)
  32. Yang Q, "Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases", J. Proteomics, 168, pp.53~65 (2017)
  33. Yang Q, "Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers", Oncotarget, 9, pp.3996~ (2018)
  34. Yu J, "Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach", Sci. Rep, 7, pp.14265~ (2017)
  35. Fan NJ, "Macrophage mannose receptor 1 and S100A9 were identified as serum diagnostic biomarkers for colorectal cancer through a label-free quantitative proteomic analysis", Cancer Biomarkers, 16, pp.235~243 (2016)
  36. Kirana C, "Combination of laser microdissection, 2D-DIGE and MALDITOF MS to identify protein biomarkers to predict colorectal cancer spread", Clin. Proteomics, 16, pp.3~ (2019)
  37. van Huizen NA, "Up-regulation of collagen proteins in colorectal liver metastasis compared with normal liver tissue", J. Biol. Chem, 294, pp.281~289 (2019)
  38. Lalmahomed ZS, "Hydroxylated collagen peptide in urine as biomarker for detecting colorectal liver metastases", Am. J. Cancer Res, 6, pp.321~ (2016)
  39. Clarke CN, "Proteomic features of colorectal cancer identify tumor subtypes independent of oncogenic mutations and independently predict relapse-free survival", Ann. Surg. Oncol, 24, pp.4051~4058 (2017)
  40. Kudryavtseva AV, "Important molecular genetic markers of colorectal cancer", Oncotarget, 7, pp.53959~ (2016)
  41. Koncina E, "Prognostic and predictive molecular biomarkers for colorectal cancer : updates and challenges", Cancers, 12, pp.319~ (2020)
  42. Ponomaryova AA, "Genomic and transcriptomic research in the discovery and application of colorectal cancer circulating markers", Int. J. Mol. Sci, 24, pp.12407~ (2023)
  43. Capuano E, "The behavior of dietary fiber in the gastrointestinal tract determines its physiological effect", Crit. Rev. Food Sci. Nutr, 57, pp.3543~3564 (2017)
  44. Fu J, "Dietary fiber intake and gut microbiota in human health", Microorganisms, 10, pp.2507~ (2022)
  45. Goodman BE, "Insights into digestion and absorption of major nutrients in humans", Adv. Physiol. Edu, 34, pp.44~53 (2010)
  46. Southgate DA, "How much and what classes of carbohydrate reach the colon", Eur. J. Cancer Prev. Supple, 2, pp.S81~S82 (1998)
  47. Afshin A, "Health effects of dietary risks in 195 countries, 1990–2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 393, pp.1958~1972 (2019)
  48. Musso G, "Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes", Ann. Rev. Med, 62, pp.361~380 (2011)
  49. Leeming ER, "Effect of diet on the gut microbiota : rethinking intervention duration", Nutrients, 11, pp.2862~ (2019)
  50. Śliżewska K, "The role of probiotics in cancer prevention", Cancers, 13, pp.20~ (2020)
  51. Wong SH, "Gut microbiota in colorectal cancer : mechanisms of action and clinical applications", Nat. Rev. Gastroenterol. Hepatol, 16, pp.690~704 (2019)
  52. McQuade JL, "Modulating the microbiome to improve therapeutic response in cancer", Lancet Oncol, 20, pp.e77~e91 (2019)
  53. Conlon MA, "The impact of diet and lifestyle on gut microbiota and human health", Nutrients, 7, pp.17~44 (2014)
  54. Syngai GG, "Probiotics-the versatile functional food ingredients", J. Food Sci. Technol, 53, pp.921~933 (2016)
  55. Fong W, "Gut microbiota modulation : a novel strategy for prevention and treatment of colorectal cancer", Oncogene, 39, pp.4925~4943 (2020)
  56. Longhi G, "Microbiota and cancer : the emerging beneficial role of bifidobacteria in cancer immunotherapy", Front. Microbiol, 11, pp.575072~ (2020)
  57. Zhao J, "Potential ability of probiotics in the prevention and treatment of colorectal cancer", Clin. Med. Insights Oncol, 17, pp.11795549231188225~ (2023)
  58. Hardy H, "Probiotics, prebiotics and immunomodulation of gut mucosal defences : homeostasis and immunopathology", Nutrients, 5, pp.1869~1912 (2013)
  59. Thoda C, "Immunomodulatory properties of probiotics and their derived bioactive compounds", Appl. Sci, 13, pp.4726~ (2023)
  60. Galdeano CM, "Proposed model : mechanisms of immunomodulation induced by probiotic bacteria", Clin. Vaccine Immunol, 14, pp.485~492 (2007)
  61. Cristofori F, "Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation : a door to the body", Front. Immunol, 12, pp.578386~ (2021)
  62. Zaharuddin L, "A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer", BMC Gastroenterol, 19, pp.131~ (2019)
  63. Gopalakrishnan V SC, "Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients", Science, 359, pp.97~103 (2018)
  64. Matson V FJ, "The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients", Science, 359, pp.104~108 (2018)
  66. Huang J, "Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer", Front. Immunol, 13, pp.874922~ (2022)
  67. Yu H, "Fecal microbiota transplantation inhibits colorectal cancer progression : reversing intestinal microbial dysbiosis to enhance anti-cancer immune responses", Front. Microbiol, 14, pp.1126808~ (2023)
  68. Kaźmierczak-Siedlecka K, "Therapeutic methods of gut microbiota modification in colorectal cancer management-fecal microbiota transplantation, prebiotics, probiotics, and synbiotics", Gut Microbes, 11, pp.1518~1530 (2020)
  69. Chang CW, "Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-fluorouracil", oxaliplatin-induced toxicity in colorectal cancer, 2020, pp.21, 386~
  70. Zhao W, "Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer : an open-label, single-arm, phase II trial(RENMIN-215)", EClinicalMedicine, 66, pp.102315~ (2023)
  71. Gholipour F, "Anticancer properties of curcumin-treated Lactobacillus plantarum against the HT-29 colorectal adenocarcinoma cells", Sci. Rep, 13, pp.2860~ (2023)
  72. Tukenmez U, "The relationship between the structural characteristics of lactobacilli-EPS and its ability to induce apoptosis in colon cancer cells in vitro", Sci. Rep, 9, pp.8268~ (2019)
  73. Yue Y, "Effects of Lactobacillus acidophilus KLDS1. 0901 on proliferation and apoptosis of colon cancer cells", Front. Microbiol, 12, pp.788040~ (2022)
  74. Baldwin C, "Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis", Nutr. Cancer, 62, pp.371~378 (2010)
  75. Ghoneum M, "Selective induction of apoptosis in human gastric cancer cells by Lactobacillus kefiri(PFT), a novel kefir product", Oncol. Rep, 34, pp.1659~1666 (2015)
  76. Lee JE, "Characterization of the anti-cancer activity of the probiotic bacterium Lactobacillus fermentum using 2D vs. 3D culture in colorectal cancer cells", Biomolecules, 9, pp.557~ (2019)
  77. Konishi H, "Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis", Nat. Commun, 7, pp.12365~ (2016)
  78. Isazadeh A, "Anti-cancer effects of probiotic Lactobacillus acidophilus for colorectal cancer cell line caco-2 through apoptosis induction", Pharm. Sci, 27, pp.262~267 (2020)
  79. Salemi R, "Lactobacillusrhamnosus GG cell-free supernatant as a novel anti-cancer adjuvant", J. Transl. Med, 21, pp.195~ (2023)
  80. Wang S, "Whole peptidoglycan extracts from the Lactobacillus paracasei subsp. paracasei M5 strain exert anticancer activity in vitro", BioMed Res. Int, 2018, pp.11~ (2018)
  81. Dehghani N, "Cell cycle arrest and anti-cancer potential of probiotic Lactobacillus rhamnosus against HT-29cancer cells", Bioimpacts, 11, pp.245~252 (2021)
  82. Guo Y, "Lactobacillus acidophilus CICC 6074 inhibits growth and induces apoptosis in colorectal cancer cells in vitro and in HT-29 cells induced-mouse model", J. Funct. Foods, 75, pp.104290~ (2020)
  83. Kuugbee ED, "Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer", Dig. Dis. Sci, 61, pp.2908~2920 (2016)
  84. Tiptiri-Kourpeti A, "Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells", PLoS One, 11, pp.e0147960~ (2016)
  85. Gamallat Y, "Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model", Biomed. Pharmacother, 83, pp.536~541 (2016)
  86. Del Carmen S, "Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model", Int. Immunopharmacol, 42, pp.122~129 (2017)
  87. Chen CC, "Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue", Br. J. Nutr, 107, pp.1623~1634 (2012)
  88. Asadollahi P, "Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis", PLoS One, 15, pp.e0232930~ (2020)
  89. Ren Z, "Effect of Bifidobacterium animalis subsp. lactis SF on enhancing the tumor suppression of irinotecan by regulating the intestinal flora", Pharm. Res, 184, pp.106406~ (2022)
  90. Faghfoori Z, "Anticancer effects of bifidobacteria on colon cancer cell lines", Cancer Cell Int, 21, pp.258~ (2021)
  91. Bahmani S, "Anti-colon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742", Turkish J. Gastroenterol, 30, pp.835~ (2019)
  92. Mager LF, "Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy", Science, 369, pp.1481~1489 (2020)
  93. Kim Y, "Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by Bifidobacterium adolescentis SPM0212", Arch. Pharm. Res, 31, pp.468~473 (2008)
  94. Wei H, "Antitumor mechanisms of bifidobacteria", Oncol. Lett, 16, pp.3~8 (2018)
  95. Whelan J, "Linoleic acid", Adv. Nutr, 4, pp.311~312 (2023)
  96. Yuce M, "Conjugated linoleic acid strengthens the apoptotic effect of cisplatin in A549cells", Prostaglandins Other Lipid Mediat, 166, pp.106731~ (2023)
  97. Cho HJ, "Conjugated linoleic acid inhibits cell proliferation and ErbB3signaling in HT-29 human colon cell line", Am. J. Physiol. Gastrointest. Liver Physiol, 284, pp.G996~G1005 (2003)
  98. Kim EJ, "Trans-10, cis-12-conjugated linoleic acid inhibits Caco-2 colon cancer cell growth", Am. J. Physiol. Gastrointest. Liver Physiol, 283, pp.G357~G67 (2002)
  99. Lampen A, "Molecular and cellular effects of cis-9, trans-11-conjugated linoleic acid in enterocytes : effects on proliferation, differentiation, and gene expression", Biochim. Biophys. Acta, 1735, pp.30~40 (2005)
  100. Cheng FS, "Probiotic mixture VSL#3 : an overview of basic and clinical studies in chronic diseases", World J. Clin. Cases, 8, pp.1361~1384 (2020)
  101. Ewaschuk JB, "Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice", J. Nutr, 136, pp.1483~1487 (2006)
  102. Dubey V, "Appraisal of the possible role of PPARγ upregulation by CLA of probiotic Pediococcus pentosaceus GS4 in colon cancer mitigation", PPAR Res, 2023, pp.15~ (2023)
  103. Dubey V, "Appraisal of the anti-cancer potential of probiotic Pediococcus pentosaceus GS4 against colon cancer : in vitro and in vivo approaches", J. Funct. Foods, 23, pp.66~79 (2016)
  104. Mohammadzadeh M, "Effect of conjugated linoleic acid supplementation on inflammatory factors and matrix metalloproteinase enzymes in rectal cancer patients undergoing chemoradiotherapy", Integr. Cancer Ther, 12, pp.496~502 (2013)
  105. Dachev M, "The effects of conjugated linoleic acids on cancer : a systematic review", Adv. Biomed. Res, 9, pp.454~ (2021)
  106. Mirzaei R, "Role of microbiota-derived shortchain fatty acids in cancer development and prevention", Biomed. Pharmacother, 139, pp.111619~ (2021)
  107. Botta C, "Lactiplantibacillus plantarum inhibits colon cancer cell proliferation as function of its butyrogenic capability", Biomed. Pharmacother, 149, pp.112755~ (2022)
  108. He Y, "Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity", Cell Metab, 33, pp.988~1000 (2021)
  109. Al-Qadami GH, "Gut microbiota-derived short-chain fatty acids : impact on cancer treatment response and toxicities", Microorganisms, 10, pp.2048~ (2022)
  110. Chen J, "Effects of intestinal microbial-elaborated butyrate on oncogenic signaling pathways", Nutrients, 11, pp.1026~ (2019)
  111. Mowat C, "Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity", Front. Immunol, 14, pp.1190810~ (2023)
  112. Clarke JM, "Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats", Carcinogenesis, 29, pp.2190~2194 (2008)
  114. Kang J, "Butyrate ameliorates colorectal cancer through regulating intestinal microecological disorders", Anticancer Drugs, 34, pp.227~237 (2023)
  115. Tian Y, "Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development", J. Nutr. Biochem, 57, pp.103~109 (2018)
  116. Gomes S, "Microbiota-derived short-chain fatty acids : new road in colorectal cancer therapy", Pharmaceutics, 14, pp.2359~ (2022)
  117. Nakkarach A, "Anti-cancer and anti-inflammatory effects elicited by short chain fatty acids produced by Escherichia coli isolated from healthy human gut microbiota", Microb. Cell Fact, 20, pp.36~ (2021)
  118. Huang C, "Short-chain fatty acids reprogram metabolic profiles with the induction of reactive oxygen species production in human colorectal adenocarcinoma cells", Comput. Struct. Biotechnol. J, 21, pp.1606~1620 (2023)

관련 논문AI추천

Microbial Metabolite Dysbiosis and Colorectal CancerKim Chang H., Niekamp Patrick거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제2호The Possible Preventative Role of Lactate- and Butyrate-Producing Bacteria in Colorectal Carcinogenesis김나영, Choi Jina, Choi Soo In, Choi Yonghoon, Jang Jae Young, Kim Eun Hye, Lee Sun Min, Nam Ryoung Hee, Seok Yeong-Jae, Song Chin-Hee, Yoon Hyuk거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제4호Anticancer Effects of Gut Microbiota-Derived Short-Chain Fatty Acids in CancersCho Hyun-Soo, Son Mi-Young한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2023 · 제33권 제7호Therapeutic Potential of Lactobacillus rhamnosus DS3316 via Cell Apoptosis in Colorectal CancerCho Hyun-Soo, Kang Yunsang, Kim Dae-Soo, Kim Jinsan, Kim Sarang, Lee Jeongmin, Lee Jinkwon, Park Doo-Sang, Park Kunhyang, Tae In Hwan, Yang Haneol한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2025 · 제35권 Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy김유미, 박광천, 배지홍대한면역학회 · Immune Network2022 · 제22권 제1호Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancerBixiang Zhang, Chendong Wang, Chenyang Li, Chujun Cai, Xiaoping Chen, Zhao Huang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호

이 간행물의 다른 논문 (19건)

Synthetic Biology-Driven Microbial Therapeutics for Disease TreatmentLee Dae-Hee, Kim Tae Hyun, Cho Byung Kwanpp. 1947-1958Exploring Levansucrase Operon Regulating Levan-Type Fructooligosaccharides (L-FOSs) Production in Priestia koreensis HL12Bunterngsook Benjarat, Trakarnpaiboon Srisakul, Prongjit Daran, Lekakarn Hataikarn, Mhuantong Wuttichaipp. 1959-1968Human Placenta Extract (HPH) Suppresses Inflammatory Responses in TNF-α/IFN-γ-Stimulated HaCaT Cells and a DNCB Atopic Dermatitis (AD)-Like Mouse ModelJeon So-Hyun, 김범준, Lee Jung Min, Park A Yeon, Jang You Na, Jin Hui, Im Minju, Lee Jung Ok, Jeong Kyeongsoo, Kim Jae-Wonpp. 1969-1980Evaluation and Molecular Characterization of Colistin-Resistant Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae from the Infected Wounds of Hospitalized PatientsYasin Haya, Khan Madiha, Ijaz Munazapp. 1981-1987Analysis of Fatty Acid Compositions and Acid Values of Krill Oil Supplementary Products from the Korean MarketShim Seong Bo, Jang Hae Won, Lee Jung-Bin, Kim Bo-Kyung, Lee Ji Yun, Hong Jun-Baepp. 1988-1994
원문 보기